Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus

Volume: 9, Pages: 1 - 12
Published: Jun 1, 2018
Abstract
As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhesion molecule-1 (ICAM-1)-targeted immunotherapeutic virus. This study investigated CVA21-induced cytotoxicity in a panel of human bladder cancer cell lines, revealing a range of sensitivities largely...
Paper Details
Title
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
Published Date
Jun 1, 2018
Volume
9
Pages
1 - 12
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.